Active Biotech expands US collaboration to advance tasquinimod clinical development in myelofibrosis
Active Biotech expands US collaboration to advance tasquinimod clinical development in myelofibrosis
Lund, Sweden, August 18, 2026 – Active Biotech (NASDAQ Stockholm: ACTI) today announced it has entered a collaboration agreement with the Icahn School of Medicine at Mount Sinai, New York, US, a not-for-profit education corporation and part of the Myeloproliferative Neoplasms Research Consortium (MPN-RC), to advance the development of its clinical drug candidate tasquinimod in myelofibrosis.
“We are honored and very pleased to initiate this collaboration with the Icahn School of Medicine, a leading center in translational cancer research,” said Active Biotech’s CEO Helén Tuvesson. “This partnership will further strengthen the scientific foundation for tasquinimod in myelofibrosis and support our ambition to accelerate the patient enrollment in the US through MPN-RC.”
The collaboration involves a preclinical research program aimed at further detailing and validating the therapeutic potential of tasquinimod in myelofibrosis, while laying the foundation for expanding the ongoing clinical program for tasquinimod in US through a partnership with MPN-RC, a network of leading research investigators at major US institutions dedicated to developing improved treatments for myeloproliferative neoplasms. In addition to Mount Sinai Health System, New York, the MPN-RC includes sites such as Memorial Sloan Kettering Cancer Center, New York, Moffit Cancer Center, Tampa, Atrium Health Wake Forest, Winston Salem and Yale School of Medicine, New Haven.
“We are excited to partner with Active Biotech and to start working with tasquinimod, an agent with a novel mode of action in myelofibrosis. We believe these studies will provide valuable insights into the therapeutic potential of tasquinimod, both as a single agent and in combination with other treatments of interest,” said Dr. Ronald Hoffman, Director of Myeloproliferative Disorders Research Program at Icahn School of Medicine, Mount Sinai.
The primary objective of the preclinical program is to evaluate the anti-tumor activity of tasquinimod both as a monotherapy and in combination with selected treatments of strategic interest. The studies will be conducted using advanced cellular models based on patient-derived material, providing a translationally relevant framework to assess therapeutic potential.
Clinical studies of tasquinimod in myelofibrosis are currently ongoing in the US at MD Anderson Cancer Center in Texas, as well as in Europe at clinical sites within the HOVON network in the Netherlands and Germany. More information about the clinical studies is available at ClinicalTrials.gov studynumber NCT06327100 and NCT06605586